ERBB2 and non-small cell lung carcinoma: A randomized, open-label, phase 3 trial (DESTINY-Lung04, NCT05048797) is currently evaluating T-Dxd compared to standard of care in NSCLC patients harboring HER2 exon 19 or 20 mutations in a first line setting.